2016 editions
- December 2016
Joao Incio on mechanisms to explain why obesity promotes cancer. - November 2016
Mike Stratton on how mutational changes in a cancer genome can point to the cause of the cancer. - October 2016
Ruth Muschel on a new target for treatments for colorectal cancer. - September 2016
Freddie Hamdy on the effectiveness of treatments for prostate cancer. - August 2016
Moshe Oren discusses the effects of the microenvironment on cancer cells. - July 2016
Richard Gilbertson on the 'bad luck hypothesis' for the cause of cancer. - June 2016
Key advances in clinical trials. - May 2016
Mark Lemmon on the underlying biochemistry of cancer. - April 2016
Roger Stupp on using alternating electric fields as treatment. - March 2016
Charlotte Vrinten on public perception of deaths from cancer. - February 2016
Guillermo Garcia-Manero on myelodysplastic syndromes (MDS). - December 2015/January 2016
Nazneen Rahman on germline genetic screening in ovarian cancer.
EJC News Focus – January 2014
What's in store in 2014?
What developments are you hoping to see in 2014? Positive results from practice-changing trials that will have a dramatic effect for patients? New approaches in research that harness Big Data and allow every patient experience to count towards common knowledge? A new focus on the epigenome? Or perhaps, more pragmatically, widespread implementation of the evidence we already have?
In this month's EJC News Focus, Helen Saul asks the Presidents of various cancer societies what they'll be looking out for in the coming year. Graeme Poston (ESSO), Cornelis van de Velde (ECCO), Birgitte Grube (EONS), Martine Piccart (ESMO), Vincenzo Valentini (ESTRO) and Moshe Oren (EACR) give us their predictions for cancer in 2014.